MA34449B1 - Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase - Google Patents

Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase

Info

Publication number
MA34449B1
MA34449B1 MA35635A MA35635A MA34449B1 MA 34449 B1 MA34449 B1 MA 34449B1 MA 35635 A MA35635 A MA 35635A MA 35635 A MA35635 A MA 35635A MA 34449 B1 MA34449 B1 MA 34449B1
Authority
MA
Morocco
Prior art keywords
dry powder
powder formulation
phosphodiesterase inhibitor
relates
phosphodiesterase
Prior art date
Application number
MA35635A
Other languages
English (en)
Inventor
Daniela Cocconi
Francesca Schiaretti
Roberto Bilzi
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MA34449B1 publication Critical patent/MA34449B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

L'invention concerne une formulation pharmaceutique sous la forme d'une poudre sèche pouvant être inhalée, comprenant des particules d'un inhibiteur de la phosphodiestérase-4 en tant que principe actif. L'invention concerne également son procédé de préparation et son utilisation dans la prévention et/ou le traitement d'une maladie respiratoire, telle que l'asthme et la maladie pulmonaire obstructive chronique (COPD).
MA35635A 2010-08-03 2011-07-27 Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase MA34449B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10171748 2010-08-03
PCT/EP2011/062872 WO2012016889A2 (fr) 2010-08-03 2011-07-27 Formulation de poudre sèche comprenant un inhibiteur de phosphodiestérase

Publications (1)

Publication Number Publication Date
MA34449B1 true MA34449B1 (fr) 2013-08-01

Family

ID=43262631

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35635A MA34449B1 (fr) 2010-08-03 2011-07-27 Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase

Country Status (36)

Country Link
US (2) US9132121B2 (fr)
EP (2) EP3246016A1 (fr)
JP (1) JP6004233B2 (fr)
KR (1) KR101805958B1 (fr)
CN (2) CN103052379A (fr)
AR (1) AR082443A1 (fr)
AU (1) AU2011287711B2 (fr)
BR (1) BR112013002506A2 (fr)
CA (1) CA2807256C (fr)
CL (1) CL2013000293A1 (fr)
CO (1) CO6690744A2 (fr)
CY (1) CY1120605T1 (fr)
DK (1) DK2600830T3 (fr)
EA (2) EA027692B1 (fr)
ES (1) ES2664175T3 (fr)
GE (1) GEP20156343B (fr)
HR (1) HRP20180717T1 (fr)
HU (1) HUE037620T2 (fr)
IL (1) IL224517B (fr)
LT (1) LT2600830T (fr)
MA (1) MA34449B1 (fr)
ME (1) ME03022B (fr)
MX (1) MX346424B (fr)
MY (1) MY179703A (fr)
NO (1) NO2600830T3 (fr)
NZ (1) NZ606548A (fr)
PE (2) PE20171256A1 (fr)
PL (1) PL2600830T3 (fr)
PT (1) PT2600830T (fr)
RS (1) RS57061B1 (fr)
SG (1) SG187258A1 (fr)
SI (1) SI2600830T1 (fr)
TR (1) TR201807012T4 (fr)
UA (1) UA112296C2 (fr)
WO (1) WO2012016889A2 (fr)
ZA (1) ZA201300870B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
WO2008095136A2 (fr) 2007-01-31 2008-08-07 Henkin Robert I Procédés de détection de substances biologiques
EP2022783A1 (fr) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. Dérivés d'alcools 1-phényl-2-pyridinylalkyliques en tant qu'inhibiteurs de la phosphodiestérase
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2216327A1 (fr) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoate de (1-Phenyl-2-Pyridin-4-yl)ethyle en tant qu'inhibiteurs de phosphodiestérase
EP2600829B1 (fr) 2010-08-03 2017-06-14 Chiesi Farmaceutici S.p.A. Formulation pharmaceutique comprenant un inhibiteur de phosphodiestérase
WO2012168226A1 (fr) 2011-06-06 2012-12-13 Chiesi Farmaceutici S.P.A. Dérivés d'alcools 1-phényl-2-pyridinyl alkyliques utilisés en tant qu'inhibiteurs de phosphodiestérase
EP2916868B1 (fr) 2012-11-08 2022-05-11 Rhizen Pharmaceuticals S.A. Compositions pharmaceutiques contenant un inhibiteur de pde4 et un inhibiteur de pi3 kinase delta ou un double inhibiteur de pi3 kinase delta et gamma
US20160030435A1 (en) * 2013-03-15 2016-02-04 Robert I HENKIN Phosphodiesterase inhibitor treatment
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
HUE046637T2 (hu) 2013-10-22 2020-03-30 Chiesi Farm Spa Eljárás PDE4-inhibitor elõállítására
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
WO2015089105A1 (fr) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Formulations en poudre d'inhibiteur pde5 et procédés y associés
CN104800192A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入粉雾剂及制备方法
WO2015126944A1 (fr) 2014-02-18 2015-08-27 Henkin Robert I Procédés et compositions permettant de diagnostiquer et de traiter une perte et/ou une distorsion du goût ou de l'odorat
US20180021256A1 (en) 2014-07-09 2018-01-25 Arven Ilac Sanayi Ve Ticaret A.S. Process for the preparation of formulations for inhalation
WO2017089347A1 (fr) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Procédés et compositions pharmaceutiques pour le traitement de mélanomes résistant aux inhibiteurs de braf
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
KR101859750B1 (ko) * 2017-09-13 2018-05-21 제일에스엠피(주) 고정식 열 저장 운반장치
KR101859752B1 (ko) * 2017-09-13 2018-05-21 심원 조립식 열 저장 운반장치
WO2023117985A1 (fr) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Formulations de poudre sèche remplies dans un inhalateur présentant une résistance à l'humidité améliorée
WO2023208982A1 (fr) 2022-04-27 2023-11-02 Chiesi Farmaceutici S.P.A. Forme cristalline d'un inhibiteur de pde4
WO2024027901A1 (fr) 2022-08-02 2024-02-08 Chiesi Farmaceutici S.P.A. Biomarqueur prédictif de réponse clinique à un inhibiteur de pde4
WO2024062005A1 (fr) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Inhalateur à capsule pour l'administration d'un inhibiteur de phosphodiestérase-4
WO2024062006A1 (fr) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Inhalateur à capsule pour l'administration d'un inhibiteur de phosphodiestérase-4
WO2024062007A1 (fr) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Inhalateur à capsule pour l'administration d'un inhibiteur de phosphodiestérase-4

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19841248A1 (de) 1997-09-12 1999-04-29 Fraunhofer Ges Forschung Demonstrationseinrichtung in Form eines Lebewesens
DE59801018D1 (de) 1997-09-16 2001-08-16 Trench Switzerland Ag Basel Spannungsteiler
EP1158958B1 (fr) 1999-03-05 2007-06-06 CHIESI FARMACEUTICI S.p.A. Compositions pharmaceutiques en poudre ameliorees pour inhalation
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
EP2266549B1 (fr) 2000-06-27 2019-08-07 Vectura Limited Procedé permettant de produire des particules destinées à être utilisées dans une composition pharmaceutique
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
DK1386630T3 (da) 2002-07-31 2006-09-11 Chiesi Farma Spa Pulverinhalator
DE10255387A1 (de) * 2002-11-28 2004-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Tiotropium-haltige Pulverformulierung für die Inhalation
GB0326632D0 (en) * 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
BRPI0610877A2 (pt) * 2005-06-06 2010-08-03 Hoffmann La Roche compostos, processo para a manufatura dos compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de l-cpt1 e utilização dos mesmos
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP2022783A1 (fr) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. Dérivés d'alcools 1-phényl-2-pyridinylalkyliques en tant qu'inhibiteurs de la phosphodiestérase
EP2070913A1 (fr) * 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Dérivés d'ester en tant qu'inhibiteurs de la phosphodiestérase
EP2216327A1 (fr) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoate de (1-Phenyl-2-Pyridin-4-yl)ethyle en tant qu'inhibiteurs de phosphodiestérase
EP2600829B1 (fr) 2010-08-03 2017-06-14 Chiesi Farmaceutici S.p.A. Formulation pharmaceutique comprenant un inhibiteur de phosphodiestérase
WO2012168226A1 (fr) 2011-06-06 2012-12-13 Chiesi Farmaceutici S.P.A. Dérivés d'alcools 1-phényl-2-pyridinyl alkyliques utilisés en tant qu'inhibiteurs de phosphodiestérase
HUE046637T2 (hu) 2013-10-22 2020-03-30 Chiesi Farm Spa Eljárás PDE4-inhibitor elõállítására

Also Published As

Publication number Publication date
EA027692B1 (ru) 2017-08-31
HUE037620T2 (hu) 2018-09-28
MX2013001172A (es) 2013-03-07
CO6690744A2 (es) 2013-06-17
CL2013000293A1 (es) 2013-05-03
EP2600830B1 (fr) 2018-02-21
AU2011287711B2 (en) 2016-10-27
WO2012016889A2 (fr) 2012-02-09
EA024922B1 (ru) 2016-11-30
IL224517B (en) 2018-04-30
US9308200B2 (en) 2016-04-12
AU2011287711A1 (en) 2013-02-21
CN106890165A (zh) 2017-06-27
PT2600830T (pt) 2018-04-02
EP2600830A2 (fr) 2013-06-12
CN103052379A (zh) 2013-04-17
EP3246016A1 (fr) 2017-11-22
CY1120605T1 (el) 2019-12-11
SI2600830T1 (en) 2018-05-31
HRP20180717T1 (hr) 2018-07-13
BR112013002506A2 (pt) 2016-05-31
MY179703A (en) 2020-11-11
KR101805958B1 (ko) 2017-12-07
WO2012016889A3 (fr) 2012-04-19
CA2807256A1 (fr) 2012-02-09
PE20130601A1 (es) 2013-05-30
LT2600830T (lt) 2018-04-10
US9132121B2 (en) 2015-09-15
EA201390049A1 (ru) 2013-05-30
EA201690541A1 (ru) 2016-07-29
ES2664175T3 (es) 2018-04-18
AR082443A1 (es) 2012-12-05
JP6004233B2 (ja) 2016-10-05
KR20130094784A (ko) 2013-08-26
ME03022B (fr) 2018-10-20
ZA201300870B (en) 2014-04-30
JP2013532705A (ja) 2013-08-19
US20150342936A1 (en) 2015-12-03
TR201807012T4 (tr) 2018-06-21
RS57061B1 (sr) 2018-06-29
MX346424B (es) 2017-03-21
CA2807256C (fr) 2018-08-28
PL2600830T3 (pl) 2018-08-31
GEP20156343B (en) 2015-08-10
UA112296C2 (uk) 2016-08-25
NZ606548A (en) 2015-02-27
US20120031403A1 (en) 2012-02-09
PE20171256A1 (es) 2017-08-28
NO2600830T3 (fr) 2018-07-21
SG187258A1 (en) 2013-03-28
DK2600830T3 (en) 2018-03-12

Similar Documents

Publication Publication Date Title
MA34449B1 (fr) Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase
MA34765B1 (fr) Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci
MA38397A1 (fr) Agglomérats inhalables de particules de support poreuses et médicament micronisé
MA33299B1 (fr) Nouvelle formulation de naproxène
MA34326B1 (fr) Formulation de poudre sèche comprenant un médicament antimuscarinique
MA33295B1 (fr) Nouvelle formulation de diclofénac
BRPI0610321B8 (pt) imidazoquinolinas como inibidores de lipídeo cinase, seu uso e seu processo de preparação, e preparação farmacêutica
BR112012019374A2 (pt) composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo
MA33488B1 (fr) Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
MA32230B1 (fr) Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one
MX344787B (es) Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara.
CN107406464A8 (zh) 精氨酸酶抑制剂及其治疗用途
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
WO2011151722A3 (fr) Méthodes et compositions de traitement pharmaceutique par voie orale
MA46268B1 (fr) Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma
PH12014501545A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
WO2011093818A3 (fr) Compositions pharmaceutiques comprenant du salmétérol et du fluticasone
MA34106B1 (fr) Combinaison de composés organiques
MA33705B1 (fr) Compositions pour l'inhalation comprenant de l'acide de montelukast et un inhibiteur de la pde-4 ou un corticosteroide inhale
JP2011500731A5 (fr)
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
WO2013181217A3 (fr) Nouveaux composés et nouvelles compositions pour le traitement de troubles ou de maladies du contrôle de la respiration
JP6225161B2 (ja) 呼吸器疾患の予防治療剤